Brian C. Stephenson Sells 24,424 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CFO Brian C. Stephenson sold 24,424 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $14.01, for a total value of $342,180.24. Following the completion of the transaction, the chief financial officer now owns 36,408 shares of the company’s stock, valued at $510,076.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

BridgeBio Pharma Trading Down 1.9 %

Shares of NASDAQ BBIO opened at $13.72 on Friday. BridgeBio Pharma, Inc. has a 12-month low of $5.74 and a 12-month high of $19.94. The company has a market cap of $2.20 billion, a P/E ratio of -4.83 and a beta of 0.71. The stock has a fifty day moving average price of $14.73 and a 200 day moving average price of $11.57.

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) last announced its quarterly earnings results on Thursday, May 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $1.83 million during the quarter, compared to analysts’ expectations of $3.23 million. During the same period in the prior year, the company posted ($1.35) EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that BridgeBio Pharma, Inc. will post -3.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on BBIO shares. Cowen started coverage on BridgeBio Pharma in a report on Monday, February 6th. They issued an “outperform” rating for the company. The Goldman Sachs Group upped their price objective on BridgeBio Pharma from $20.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, March 7th. Bank of America upped their price objective on BridgeBio Pharma from $15.00 to $18.00 in a report on Tuesday, March 7th. Evercore ISI assumed coverage on BridgeBio Pharma in a report on Wednesday, April 19th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Mizuho upped their price objective on BridgeBio Pharma from $23.00 to $29.00 in a report on Monday, May 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, BridgeBio Pharma presently has an average rating of “Buy” and a consensus target price of $26.63.

Institutional Trading of BridgeBio Pharma

Several large investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. increased its holdings in BridgeBio Pharma by 8.6% in the 1st quarter. Rockefeller Capital Management L.P. now owns 49,202 shares of the company’s stock valued at $815,000 after purchasing an additional 3,885 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in BridgeBio Pharma in the 1st quarter valued at about $1,199,000. Perceptive Advisors LLC boosted its position in BridgeBio Pharma by 12.4% in the 1st quarter. Perceptive Advisors LLC now owns 1,907,033 shares of the company’s stock valued at $31,619,000 after buying an additional 210,000 shares during the last quarter. Sandia Investment Management LP purchased a new position in BridgeBio Pharma in the 1st quarter valued at about $83,000. Finally, Squarepoint Ops LLC boosted its position in BridgeBio Pharma by 573.6% in the 1st quarter. Squarepoint Ops LLC now owns 247,568 shares of the company’s stock valued at $4,105,000 after buying an additional 210,814 shares during the last quarter. 96.46% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

(Get Rating)

BridgeBio Pharma, Inc engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.